Stock HAE HAEMONETICS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Haemonetics Corporation

Equities

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:00:02 2024-06-07 pm EDT 		5-day change 1st Jan Change
85.61 USD -2.03% Intraday chart for Haemonetics Corporation +1.82% +0.12%
May. 29 Haemonetics Insider Sold Shares Worth $1,144,208, According to a Recent SEC Filing MT
May. 29 Haemonetics Insider Sold Shares Worth $775,253, According to a Recent SEC Filing MT

Valuation

Fiscal Period: Marzo 2020 2021 2022 2023 2024 2025 2026 2027
Capitalization 1 5,127 5,711 3,143 4,044 4,335 4,362 - -
Enterprise Value (EV) 1 5,372 6,226 3,657 4,526 4,335 4,362 4,362 4,362
P/E ratio 68.9 x 72.5 x 73.2 x 35.8 x 37.3 x 28.5 x 21.2 x 15.4 x
Yield - - - - - 2.34% 2.34% 2.34%
Capitalization / Revenue 5.19 x 6.56 x 3.16 x 3.46 x 3.31 x 3.11 x 2.96 x 2.72 x
EV / Revenue 5.19 x 6.56 x 3.16 x 3.46 x 3.31 x 3.11 x 2.96 x 2.72 x
EV / EBITDA 16.7 x 23.9 x 11 x 13.3 x 11.7 x 10.6 x 9.86 x 9.68 x
EV / FCF 46.8 x - - - - 15 x 17.2 x 14.5 x
FCF Yield 2.14% - - - - 6.65% 5.8% 6.9%
Price to Book 9 x 7.88 x 4.19 x 4.94 x - - - -
Nbr of stocks (in thousands) 50,298 50,822 51,112 50,448 50,786 50,953 - -
Reference price 2 101.9 112.4 61.50 80.17 85.35 85.61 85.61 85.61
Announcement Date 5/5/20 5/13/21 5/10/22 5/11/23 5/9/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Marzo 2020 2021 2022 2023 2024 2025 2026 2027
Net sales 1 988.5 870.5 993.2 1,169 1,309 1,400 1,475 1,604
EBITDA 1 306.7 238.9 284.9 304.7 370.1 413.3 442.5 450.5
EBIT 1 218 154.6 187.1 218.4 276.5 329 378.2 437.7
Operating Margin 22.06% 17.76% 18.84% 18.69% 21.12% 23.5% 25.64% 27.29%
Earnings before Tax (EBT) 1 87.15 72.91 63.63 141.4 151.9 192.9 255.6 318.9
Net income 1 76.53 79.47 43.38 115.4 117.6 152.9 216.9 287.4
Net margin 7.74% 9.13% 4.37% 9.87% 8.98% 10.92% 14.7% 17.91%
EPS 2 1.480 1.550 0.8400 2.240 2.290 3.003 4.030 5.573
Free Cash Flow 1 109.5 - - - - 290.1 253 301.1
FCF margin 11.07% - - - - 20.72% 17.15% 18.77%
FCF Conversion (EBITDA) 35.69% - - - - 70.19% 57.17% 66.84%
FCF Conversion (Net income) 143.04% - - - - 189.68% 116.65% 104.78%
Dividend per Share 2 - - - - - 2.000 2.000 2.000
Announcement Date 5/5/20 5/13/21 5/10/22 5/11/23 5/9/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4 2026 Q1
Net sales 1 259.8 265 261.5 297.5 305.3 304.4 311.3 318.2 336.2 343.3 335 345.4 359.6 360.3 346.4
EBITDA 1 71.05 71.41 64.26 67.68 81.99 76.88 92.78 90.84 96.9 89.24 87.6 93.62 102 105 97.74
EBIT 1 58.83 46.59 44.89 60.6 59.01 53.94 70.23 68.34 73.36 64.6 73.83 79.42 86.91 88.86 83.09
Operating Margin 22.65% 17.58% 17.17% 20.37% 19.33% 17.72% 22.56% 21.48% 21.82% 18.82% 22.03% 22.99% 24.17% 24.67% 23.99%
Earnings before Tax (EBT) 1 31.39 15.33 25.49 41.06 42.22 32.63 51.59 32.83 44.03 23.41 35.8 44.47 52.62 59.97 52.24
Net income 1 23.23 9.741 19.88 33.2 32.94 29.38 41.04 24.91 31.24 20.37 28.07 34.68 41.94 48.24 40.48
Net margin 8.94% 3.68% 7.6% 11.16% 10.79% 9.65% 13.18% 7.83% 9.29% 5.93% 8.38% 10.04% 11.66% 13.39% 11.69%
EPS 2 0.4500 0.1900 0.3800 0.6400 0.6400 0.5700 0.8000 0.4800 0.6100 0.4000 0.5833 0.6967 0.8333 0.8967 0.8100
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/8/22 5/10/22 8/10/22 11/7/22 2/7/23 5/11/23 8/8/23 11/2/23 2/8/24 5/9/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 245 515 514 481 - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) 0.7994 x 2.157 x 1.805 x 1.58 x - - - -
Free Cash Flow 1 109 - - - - 290 253 301
ROE (net income / shareholders' equity) 27.3% 18.3% 17.9% 19.9% - 24% 22.5% 19.9%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 11.30 14.30 14.70 16.20 - - - -
Cash Flow per Share - - - - - - - -
Capex 1 48.8 37 - - - 71.5 73.9 81.9
Capex / Sales 4.93% 4.26% - - - 5.11% 5.01% 5.11%
Announcement Date 5/5/20 5/13/21 5/10/22 5/11/23 5/9/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Haemonetics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
85.61 USD
Average target price
113.5 USD
Spread / Average Target
+32.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
HAEMONETICS CORPORATION Stock Haemonetics Corporation
+0.12% 4.36B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.26% 187B
MEDTRONIC PLC Stock Medtronic plc
+2.05% 110B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-1.31% 69.54B
CENCORA, INC. Stock Cencora, Inc.
+14.65% 46.37B
DEXCOM, INC. Stock DexCom, Inc.
-6.69% 46.05B
HOYA CORPORATION Stock Hoya Corporation
+7.97% 42.54B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+18.60% 30.72B
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-6.87% 23.32B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-10.63% 22.92B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. HAE Stock
  4. Financials Haemonetics Corporation